Phaseline

Targets › HDAC (class I/II)

HDAC (class I/II): drug programs, companies and trials

26 programs from 24 companies in 105 trials: 51 Phase 1, 42 Phase 2, 11 Phase 3, 1 Phase 4; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Open in Phaseline: the race on HDAC (class I/II), likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Novartispanobinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 4Primary Myelofibrosis; Sickle Cell DiseaseApr 2032
ItalfarmacoGivinostat Hydrochloride
Histone deacetylase inhibitor
HDAC (class I/II)Phase 3Polycythemia Vera; Duchenne Muscular Dystrophy; Chronic Myeloproliferative NeoplasmsDec 2026
Xynomic PharmaceuticalsAbexinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 3Renal Cell Carcinoma; Lymphoma, Follicular; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma …Dec 2026
Chengdu Zenitar Biomedical TechnologyPurinostat Mesylate for Injection
Class Ia and IIb HDAC selective inhibitor
HDAC (class I/II)Phase 3Recurrent and Refractory Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma,DLBCL; Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL); Relapsed or Refractory Multiple Myeloma (RRMM) …Dec 2026
National Cancer Institute (NCI)Entinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 3Anatomic Stage III Breast Cancer AJCC v8; Clear Cell Renal Cell Carcinoma; Advanced Malignant Solid NeoplasmFeb 2027
The First Affiliated Hospital with Nanjing Medical UniversityChidemide
Histone deacetylase (HDAC) inhibitor
HDAC (class I/II)Phase 3Newly Diagnosed Peripheral T-cell LymphomaFeb 2028
Chipscreen BiosciencesTucidinostat
HDAC inhibitor
HDAC (class I/II)Phase 3Colorectal Cancer; Lymphoma, T-Cell, PeripheralMay 2028
Acrotech BiopharmaBelinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 3Peripheral T Cell Lymphoma; Locally Advanced Unresectable Primary Central Chondrosarcoma; Carcinoma, Neuroendocrine; Metastatic Uveal Melanoma …Jul 2030
Tianjin Medical University Cancer Institute and HospitalChidamide
Histone deacetylase (HDAC) inhibitor
HDAC, HDAC (class I/II)Phase 2Diffuse Large B-Cell Lymphoma-Recurrent; Metastatic Pancreatic Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Neuroblastoma (NB)Dec 2026
The First Affiliated Hospital with Nanjing Medical UniversityChidamide
Selective histone deacetylase (HDAC) inhibitor
HDAC (class I/II)Phase 2Double Expressor DLBCL; ChidamideMar 2027
Great Novel Therapeutics Biotech & MedicalsChidamide
Histone deacetylase (HDAC) inhibitor
HDAC (class I/II)Phase 2Relapsed or Refractory Peripheral T-cell Lymphoma; Metastatic Microsatellite-stable Colorectal Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Colorectal Cancer Metastatic …Jun 2027
Stephen Chan LamZabadinostat (CXD101)
Histone deacetylase (HDAC) inhibitor
HDAC (class I/II)Phase 2HCCDec 2027
University of VirginiaRomidepsin
Histone deacetylase inhibitor
HDAC (class I/II)Phase 2PTCL; Lymphoma, T-CellJun 2028
Centre Leon BerardChemotherapy + Valproate
Multi-agent chemotherapy (vincristine, carboplatin, methotrexate, cyclophosphamide, cispla
HDAC (class I/II)Phase 2Childhood EpendymomaJun 2028
University of MiamiQuisinostat
Histone deacetylase inhibitor
HDAC (class I/II)Phase 2Uveal MelanomaMay 2030
Shanghai Jiao Tong University School of MedicineChidamide
HDAC3 inhibitor
HDAC (class I/II)Phase 2APL–
Jonsson Comprehensive Cancer CenterMocetinostat
Histone deacetylase 1 inhibitor; Histone deacetylase 2 inhibitor; Histone deacetylase 3 inhibitor
HDAC (class I/II)Phase 1RhabdomyosarcomaDec 2026
Unravel BiosciencesVorinostat
Histone deacetylase 1 inhibitor; Histone deacetylase 3 inhibitor; Histone deacetylase 6 inhibitor
HDAC (class I/II)Phase 1Rett Syndrome; Pitt Hopkins Syndrome; Castration-Resistant Prostate Carcinoma; Metastatic Uveal Melanoma …Dec 2026
Dana-Farber Cancer InstituteRicolinostat (ACY-1215)
Histone deacetylase 6 inhibitor
HDAC (class I/II)Phase 1Recurrent Chronic Lymphoid LeukemiaApr 2027
Memorial Sloan Kettering Cancer CenterMocetinostat
Histone deacetylase 1 inhibitor; Histone deacetylase 2 inhibitor; Histone deacetylase 3 inhibitor
HDAC (class I/II)Phase 1Lung CancerJul 2027
Daiichi SankyoValemetostat (DS-3201b)
Histone deacetylase inhibitor
HDAC (class I/II)Phase 1Metastatic Castration-resistant Prostate Cancer; Aggressive Variant Prostate Carcinoma; Extensive-stage Small-cell Lung Cancer; Lymphoma …Jan 2028
Novelwise PharmaceuticalNBM-BMX
HDAC8 inhibitor
HDAC (class I/II)Phase 1Metastatic Uveal Melanoma; Malignant Neoplasm; Malignant Neoplasm of BrainMar 2028
H. Lee Moffitt Cancer Center and Research InstituteRomidepsin
Histone deacetylase inhibitor
HDAC (class I/II)Phase 1Bladder CancerApr 2028
Jubilant TherapeuticsJBI-802
CoREST inhibitor dual targeting LSD1 and HDAC6
LSD1, HDAC (class I/II)Phase 1Essential Thrombocythemia (ET); Lung Cancer (NSCLC)Jun 2028
H. Lee Moffitt Cancer Center and Research InstituteDomatinostat
HDAC inhibitor
HDAC (class I/II)Phase 1SarcomaAug 2031
Priyanka SharmaRomidepsin
Histone deacetylase inhibitor
HDAC (class I/II)Phase 1Triple-Negative Breast Cancer–

Conditions

Metastatic Uveal Melanoma (3) Diffuse Large B-Cell Lymphoma (DLBCL) (3) Peripheral T Cell Lymphoma (3) Duchenne Muscular Dystrophy (3) Breast Cancer (2) Lung Cancer (2) Acute Myeloid Leukemia (2) Diffuse Large B-Cell Lymphoma (2) Leukemia, Myeloid, Acute (2) Anatomic Stage III Breast Cancer AJCC v8 (2) HCC (2) Renal Cell Carcinoma (1)

Modalities

small molecule (16), mixed (8), antibody (2)

Companies

H. Lee Moffitt Cancer Center and Research Institute (2) The First Affiliated Hospital with Nanjing Medical University (2) Xynomic Pharmaceuticals (1) Shanghai Jiao Tong University School of Medicine (1) Jubilant Therapeutics (1) Unravel Biosciences (1) Great Novel Therapeutics Biotech & Medicals (1) Jonsson Comprehensive Cancer Center (1) Italfarmaco (1) Daiichi Sankyo (1) University of Virginia (1) Chengdu Zenitar Biomedical Technology (1) Tianjin Medical University Cancer Institute and Hospital (1) University of Miami (1) Acrotech Biopharma (1) Novelwise Pharmaceutical (1) National Cancer Institute (NCI) (1) Chipscreen Biosciences (1) Stephen Chan Lam (1) Dana-Farber Cancer Institute (1)

Related targets

LSD1 (1) HDAC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.